Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 134,000 shares at $62.78 ($8.6M) on 2020-06-11, disclosed to the SEC on 2020-06-12.
Scheduled sale ($8.6M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $61.97 | 16,444 | $1.0M | 11.9% |
| 2 | $62.78 | 20,043 | $1.3M | 14.6% |
| 3 | $63.79 | 18,474 | $1.2M | 13.7% |
| 4 | $64.57 | 25,039 | $1.6M | 18.8% |
| 5 | $64.79 | 28,086 | $1.8M | 21.2% |
| 6 | $65.78 | 25,914 |
| $1.7M |
| 19.8% |
| Total | $64.16 avg | 134,000 | $8.6M | 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2021-11-17 | $8.8M | — | Filing → |